Ernexa Therapeutics (ERNAW) Accumulated Depreciation (2012 - 2025)

Ernexa Therapeutics has reported Accumulated Depreciation for 13 years, with the latest figure at $197000.0 in Q4 2025.

• For the quarter ending Q4 2025, Accumulated Depreciation rose 14.53% year-over-year to $197000.0; the trailing twelve-month figure through Dec 2025 stood at $197000.0 (up 14.53% YoY), and the FY2025 full-year result was $197000.0, up 14.53% from the prior year.
• Accumulated Depreciation for Q4 2025 stood at $197000.0, up from $172000.0 in the prior quarter.
• The five-year high for Accumulated Depreciation was $207000.0 in Q4 2021, with the low at $32000.0 in Q4 2022.
• Historically, Accumulated Depreciation has averaged $144566.7 across 5 years, with a median of $158700.0 in 2021.
• Annual changes were most pronounced in 2022 — Accumulated Depreciation plunged 84.54% — and 2023, when it jumped 256.25%.
• Ernexa Therapeutics' Accumulated Depreciation stood at $207000.0 in 2021, then sank by 84.54% to $32000.0 in 2022, then jumped by 256.25% to $114000.0 in 2023, then soared by 50.88% to $172000.0 in 2024, then rose by 14.53% to $197000.0 in 2025.
• The last three Accumulated Depreciation figures came in at $197000.0 (Q4 2025), $172000.0 (Q4 2024), and $114000.0 (Q4 2023), per Business Quant data.